Dapagliflozin Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 10 mg
Reference Brands: Forxiga(US & EU)
Category:
Diabetes
Dapagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys, promoting urinary glucose excretion. It improves glycemic control, supports weight loss, lowers blood pressure, and reduces the risk of heart failure and kidney disease progression. It offers once-daily oral dosing with cardiovascular and renal protective benefits.
Dapagliflozin Tablets is available in Tablets
and strengths such as 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dapagliflozin Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dapagliflozin Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dapagliflozin, an SGLT2 inhibitor, is approved in both the USA and EU for treating type 2 diabetes, heart failure, and chronic kidney disease. In the USA, it is marketed as Farxiga®, approved via an NDA under 21 CFR, requiring robust safety labeling for risks like ketoacidosis and UTIs. In the EU, it is approved as Forxiga® through the centralized procedure by the EMA, with CTD-format submission, RMP, PSURs, and strict pharmacovigilance. Manufacturers must comply with GMP and post-marketing obligations. For regulatory consulting, global B2B sourcing, or dossier support, visit PharmaTradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing